ATE233092T1 - Verwendung von oxazolidinonderivate zur behandlung von arthritis - Google Patents

Verwendung von oxazolidinonderivate zur behandlung von arthritis

Info

Publication number
ATE233092T1
ATE233092T1 AT98960157T AT98960157T ATE233092T1 AT E233092 T1 ATE233092 T1 AT E233092T1 AT 98960157 T AT98960157 T AT 98960157T AT 98960157 T AT98960157 T AT 98960157T AT E233092 T1 ATE233092 T1 AT E233092T1
Authority
AT
Austria
Prior art keywords
treat arthritis
oxazolidinone derivatives
oxazolidinone
arthritis
psoriasis
Prior art date
Application number
AT98960157T
Other languages
English (en)
Inventor
Donald H Batts
Roger G Ulrich
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE233092T1 publication Critical patent/ATE233092T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98960157T 1997-11-18 1998-11-10 Verwendung von oxazolidinonderivate zur behandlung von arthritis ATE233092T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6568997P 1997-11-18 1997-11-18
US7129798P 1998-01-16 1998-01-16
US7366298P 1998-02-04 1998-02-04
US7524798P 1998-02-19 1998-02-19
US7767298P 1998-03-12 1998-03-12
PCT/US1998/023233 WO1999025344A1 (en) 1997-11-18 1998-11-10 Use of oxazolidinone derivatives for treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy

Publications (1)

Publication Number Publication Date
ATE233092T1 true ATE233092T1 (de) 2003-03-15

Family

ID=27535698

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98960157T ATE233092T1 (de) 1997-11-18 1998-11-10 Verwendung von oxazolidinonderivate zur behandlung von arthritis

Country Status (15)

Country Link
EP (1) EP1032386B1 (de)
JP (1) JP2001522886A (de)
KR (2) KR100589545B1 (de)
CN (2) CN1142777C (de)
AT (1) ATE233092T1 (de)
AU (1) AU743941B2 (de)
BR (1) BR9815615A (de)
CA (1) CA2303961A1 (de)
DE (1) DE69811717T2 (de)
DK (1) DK1032386T3 (de)
ES (1) ES2193592T3 (de)
NZ (1) NZ504612A (de)
PT (1) PT1032386E (de)
SI (1) SI1032386T1 (de)
WO (1) WO1999025344A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1311787A (zh) 1998-06-05 2001-09-05 阿斯特拉曾尼卡有限公司 噁唑烷酮衍生物、其制备方法以及含有它们的药物组合物
JP2003529544A (ja) * 1999-09-13 2003-10-07 インサイト・ビジョン・インコーポレイテッド 眼感染症の予防たのための局所処置
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
US6451345B1 (en) 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20050250709A1 (en) * 2003-12-19 2005-11-10 Bionaut Pharmaceuticals Anti-neoplastic agents, combination therapies and related methods
CN107456442A (zh) * 2016-06-03 2017-12-12 四川赛卓药业股份有限公司 一种噁唑烷酮化合物的亚微乳注射剂及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE146783T1 (de) * 1991-11-01 1997-01-15 Upjohn Co Substituierte aryl- und heteroaryl- phenyloxazolidinone
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO1995014684A1 (en) * 1993-11-22 1995-06-01 The Upjohn Company Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones

Also Published As

Publication number Publication date
SI1032386T1 (en) 2003-06-30
KR20050100009A (ko) 2005-10-17
BR9815615A (pt) 2000-10-24
WO1999025344A1 (en) 1999-05-27
EP1032386A1 (de) 2000-09-06
JP2001522886A (ja) 2001-11-20
DK1032386T3 (da) 2003-05-26
AU1582399A (en) 1999-06-07
KR100574307B1 (ko) 2006-04-27
DE69811717D1 (de) 2003-04-03
NZ504612A (en) 2002-08-28
HK1036591A1 (en) 2002-01-11
CN1142777C (zh) 2004-03-24
AU743941B2 (en) 2002-02-07
DE69811717T2 (de) 2003-10-16
ES2193592T3 (es) 2003-11-01
KR100589545B1 (ko) 2006-06-19
EP1032386B1 (de) 2003-02-26
PT1032386E (pt) 2003-07-31
CA2303961A1 (en) 1999-05-27
CN1299281A (zh) 2001-06-13
CN1546030A (zh) 2004-11-17
KR20010032178A (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
DE19680619D2 (de) Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
DE59409832D1 (de) Pflaster zur behandlung von nagelmykosen
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
ATE164067T1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69431056D1 (de) Substituierte oxazolyl-derivate zur behandlung von entzündungen
DE50214206D1 (de) Kombinationstherapie substituierter oxazolidinone
DE69807115D1 (de) Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms
DK0815087T3 (da) Trisubstituerede phenylderivater
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
ATE255894T1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
ATE233092T1 (de) Verwendung von oxazolidinonderivate zur behandlung von arthritis
ATE275919T1 (de) Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen
FI950403A0 (fi) Neurosuojaavia yhdisteitä
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي
ATE266027T1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
DE69830811D1 (de) Verwendung von Oxazolidinonderivaten zur Behandlung von Psoriasis
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
DE50105253D1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
NO984198L (no) FremgangsmÕte for behandling av aggresjon
DE60128130D1 (de) Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1032386

Country of ref document: EP

REN Ceased due to non-payment of the annual fee